Drugs / Cerebrolysin
last change May 2026 re-read 2 minutes ago

Cerebrolysin

also known as CBL · CBN

Peptide

Developed for
ischemic stroke · stroke disorder · traumatic brain injury · Alzheimer disease · anosmia · basilar artery occlusion · brain hypoxia - ischemia · brain infarction
+13 more · cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 · cerebral artery occlusion · cerebral palsy · cognitive disorder · developmental delay with or without epilepsy · hemorrhagic stroke · intellectual disability · intracerebral hemorrhage · vascular dementia · Bell's palsy · Down syndrome · post-COVID-19 disorder · subarachnoid hemorrhage
Investigated by
Ever Neuro Pharma GmbH · Ain Shams University · Samsung Medical Center · acromion GmbH · Assiut University · Brainomix Limited
+20 more · Cardinal Stefan Wyszynski University · Chang Gung Memorial Hospital · Clinical Institute of the Brain, Russia · Excel PharmaStudies, Inc. · Geny Research Corp. · Hospital Universitario Dr. Jose E. Gonzalez · JSW-Research Forschungslabor GmbH, Parkring 12, 8074 Grambach · Konkuk University Medical Center · Medical University of Lublin · Military Institute od Medicine National Research Institute · Poznan University of Medical Sciences · Sahar M.A. Hassanein, MD · Shaare Zedek Medical Center · Shanghai 6th People's Hospital · University Hospital Sestre Milosrdnice · University Medical Centre Ljubljana · XClinical GmbH · Yonsei University · idv Datenanalyse & Versuchsplanung · idv Datenanalyse und Versuchsplanung

Trials 26 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT06489925 Jul 2024 → May 2025 overdue basilar artery occlusion, brain infarction University Hospital Sestre Milosrdnice Not yet recruiting No outcome recorded
Phase 0 NCT06339411 May 2024 → Dec 2026 expected ischemic stroke Chang Gung Memorial Hospital Not yet recruiting No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02149875 Jan → May 2010 cerebral artery occlusion Shanghai 6th People's Hospital Completed No outcome recorded
Phase 24 trials
Phase 2 NCT05755997 Nov 2023 → Mar 2026 overdue cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 Ever Neuro Pharma GmbH Active not recruiting No outcome recorded
Phase 2 NCT02116348 Apr 2014 → Apr 2016 cerebral palsy, developmental delay with or without epilepsy, intellectual disability, traumatic brain injury Ain Shams University Unknown No outcome recorded
Phase 2 NCT01059461 Mar 2011 → Sep 2013 brain hypoxia - ischemia Sahar M.A. Hassanein, MD Completed No outcome recorded
Phase 2 NCT00911807 Oct 2004 → Apr 2008 Alzheimer disease Ever Neuro Pharma GmbH Completed No outcome recorded
Phase 34 trials
Phase 3 NCT06052787 Sep 2023 → May 2025 traumatic brain injury Ain Shams University Completed No outcome recorded
Phase 3 NCT04904341 Jan 2021 → Dec 2023 ischemic stroke Military Institute od Medicine National Research Institute Unknown No outcome recorded
Phase 3 NCT04830943 Aug 2020 → Sep 2021 anosmia Assiut University Completed No outcome recorded
Phase 3 NCT00840671 Oct 2005 → Mar 2008 stroke disorder Ever Neuro Pharma GmbH Completed No outcome recorded
Phase 412 trials
Phase 4 NCT06899464 Oct 2025 → Jan 2027 expected intracerebral hemorrhage Cardinal Stefan Wyszynski University Not yet recruiting No outcome recorded
Phase 4 NCT04427241 Jun 2023 → Sep 2026 expected hemorrhagic stroke Konkuk University Medical Center Recruiting No outcome recorded
Phase 4 NCT06078215 Jan 2023 → Jan 2025 ischemic stroke Poznan University of Medical Sciences Unknown No outcome recorded
Phase 4 NCT06273020 Nov 2022 → Nov 2024 ischemic stroke, type 2 diabetes mellitus Hospital Universitario Dr. Jose E. Gonzalez Unknown No outcome recorded
Phase 4 NCT04913831 Jun 2021 → Mar 2024 stroke disorder Yonsei University Unknown No outcome recorded
Phase 4 NCT02768571 Mar 2016 → Feb 2019 stroke disorder Samsung Medical Center Completed No outcome recorded
Phase 4 NCT02581371 Feb 2015 → Feb 2017 ischemic stroke Clinical Institute of the Brain, Russia Unknown No outcome recorded
Phase 4 NCT01606111 Sep 2013 → Jul 2015 traumatic brain injury Ever Neuro Pharma GmbH Terminated No outcome recorded
Phase 4 NCT01996761 Jan 2011 → Jan 2014 Samsung Medical Center Completed No outcome recorded
Phase 4 NCT00947531 Oct 2006 → Aug 2007 vascular dementia Ever Neuro Pharma GmbH Completed No outcome recorded
Phase not applicable3 trials
NCT07043686 Jun 2025 → Jul 2027 expected ischemic stroke University Medical Centre Ljubljana Recruiting No outcome recorded
NCT06677502 Jan 2024 → Jun 2025 overdue cognitive disorder Medical University of Lublin Enrolling by invitation No outcome recorded
NCT06070753 Oct 2023 → Jun 2024 ischemic stroke Shaare Zedek Medical Center Unknown No outcome recorded
Also used as a comparator or background therapy in 10 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03506841 Comparator Jun 2016 → Jun 2019 cerebral palsy Mansoura University Children Hospital Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT05821075 Comparator Aug 2023 → Jan 2026 overdue Bell's palsy October 6 University Recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT04124367 Comparator Jun 2021 → Mar 2022 stroke disorder Ever Neuro Pharma GmbH Terminated No outcome recorded
Phase 2 NCT04751136 Comparator Sep 2016 → Feb 2019 Down syndrome Mansoura University Children Hospital Completed No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT05124353 Comparator Apr 2021 → Apr 2023 ischemic stroke Pomeranian Medical University Szczecin Unknown No outcome recorded
Phase 2/3 NCT01787123 Comparator Dec 2013 → Jan 2019 brain aneurysm, brain ischemia, subarachnoid hemorrhage Kwong Wah Hospital Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01388738 Comparator Jan → Oct 2011 stroke disorder Clinical Institute of the Brain, Russia Completed No outcome recorded
Phase 41 trial
Phase 4 NCT06208540 Comparator Aug 2021 → Apr 2024 post-COVID-19 disorder Sherifa Ahmed Hamed Completed No outcome recorded
Phase not applicable2 trials
NCT05864677 Comparator Jan 2023 → Jun 2024 brain injury, cognitive disorder, heart disorder Medical University of Lublin Unknown No outcome recorded
NCT05288465 Background Jun 2014 → Dec 2015 hair anomaly Autonomous University of Nuevo León Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 39 sources stand behind the page.

FieldValueCited text
Known as cerebrolysin “Drug: cerebrolysinNCT04751136
36

NCT05288465

NCT04751136

NCT06208540

NCT02116348

NCT03506841

NCT05821075

NCT07043686

NCT04830943

NCT05755997

NCT06489925

NCT05124353

NCT06677502

NCT05864677

NCT06078215

NCT06070753

NCT00911807

NCT01822951

NCT06273020

NCT02768571

NCT00947531

NCT06899464

NCT01388738

NCT01996761

NCT02149875

NCT00868283

NCT06339411

NCT04904341

NCT02581371

NCT01606111

NCT01059461

NCT00840671

NCT04913831

NCT04427241

NCT06052787

NCT04124367

NCT01787123

Known as CBL “The incidence of vascular dementia (VaD) has rapidly increased over the past few decades. Although officially approved medications for VaD remain limited, cerebrolysin (CBL)...” PMID 28458021 Apr 2017
Known as CBN “Cerebrolysin (CBN) is a mixture of several neurotrophic factors and active peptides with anti-inflammatory, antioxidant, and neuroprotective actions.” PMID 34674598 Oct 2021
Modality Peptide “Cerebrolysin is a parenterally administered neuropeptide preparation approved for treatment of stroke.” PMID 29248999 Dec 2017
Route Intravenous “Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.” NCT00840671